Array BioPharma

Latest Headlines

Latest Headlines

Array's melanoma drug clears Phase III with an FDA filing in sight

Array BioPharma's new treatment for skin cancer extended survival in a Phase III trial, meeting its main goal and clearing the way for an FDA submission next year, the company said.

Moving on from Novartis, Array inks a $455M oncology deal with Pierre Fabre

Array BioPharma, hunting for partners after Novartis walked away from a pair of cancer projects, has linked up with Pierre Fabre to co-develop the treatments in an agreement worth up to $455 million.

Novartis hands off another PhIII drug to Array

That big drug swap between Novartis and GlaxoSmithKline is once again proving to be a boon to Array BioPharma. Array saw its shares spike more than 40% on Friday after the company said that Novartis is handing back rights to the Phase III BRAF inhibitor encorafenib, not long after it also scooped up the rights to binimetinib.

Oncothyreon is going it alone with Array's former breast cancer contender

Moving on from the slow demise of its Merck KGaA-partnered cancer vaccine, Seattle's Oncothyreon has bought out co-developer Array BioPharma, acquiring exclusive rights to the pair's early-stage breast cancer candidate.

Party time at Array as Novartis bows out of PhIII binimetinib cancer program

Usually, when a biotech company loses a Big Pharma development partner, the executives wind up circling the wagons in a vain attempt to defend the value of their drug. But for Boulder, CO-based Array BioPharma and its backers, Novartis' exit from its late-stage program for the MEK inhibitor binimetinib was a good occasion to throw a party.

Slumping Array aligns with Biogen on early autoimmune R&D

Array BioPharma has watched its shares fall steadily earthward since ex-partner Amgen backed out of a diabetes deal last summer, but a new deal with Big Biotech Biogen Idec sent the company up about 5% on renewed hopes for its early-stage R&D efforts.

Array slides as longtime CSO finds the exit

Array BioPharma Chief Scientific Officer Kevin Koch is leaving the biotech after 15 years, news that sent the company's shares down more than 5% on Thursday morning.

UPDATED: Cancer biotech upstart nabs $33M A round for R&D work, Array collaboration

Three months after in-licensing a preclinical cancer drug from Array BioPharma ($ARRY), the upstart biotech Loxo Oncology announced that it has a $33 million Series A lined up to fund the work ahead. 

Array slashes staff as Amgen pulls the plug on diabetes drug pact

Shares of Array BioPharma took a nasty dive Wednesday evening after Amgen pulled the plug on an ambitious four-year-old partnership to develop new Type 2 diabetes drugs. The company said it will have to ax 50 workers--20% of its staff--in response.

Celgene inks $11M inflammation deal with Array BioPharma

The arrangement with Array represents a relatively small upfront bet for Celgene, which has just forked over $100 million for an option to buy Acetylon and the Boston startup's HDAC6 inhibitor in early clinical development for myeloma.